Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Sites / University of Texas Health Science Center at San Antonio / Monroe, Brigitte Burlingame

Monroe, Brigitte Burlingame (M.S.)

Staff, University of Texas Health Science Center at San Antonio, 210-567-5944

Contact Information

Email: mailto:monroeb@uthscsa.edu
Fax:

To update contact information, please visit the Data Management and Coordinating Center.

Open Protocols

Protocol Name Biomarkers Datasets
Inflammation as a Potential Marker of Risk ad Progression for Prostate Cancer 0 0
PASS Reference Set Application: Thompson UT Health Science Center San Antonio (2014) SNPs for PCa Outcome 0 0
Release of Set Aside Funds - microRNA Biomarkers for Renal Cell Carcinoma 0 0
Upgrading Reference Set 0 0
A Methylation Panel for Bladder Cancer 0 0
Biomarker Discovery for Renal Cell Carcinoma Through Serum, Urine and Tissue Protein Profiles 0 0
Canary TMA 13 0
EDRN Pre-Validation of Multiplex Biomarker in Urine 2 0
Prostate Active Surveillance Study 2 0
Prostate-MRI 0 0
SELDI Profiling of serum and urine from patients with urologic disease in support of bladder cancer studies 0 0

Closed Protocols

Protocol Name Biomarkers Datasets
Identification of protein and genetic biomarkers of prostate cancer and risk factors for progression of disease 0 0
Prostate Upgrading Team Project 0 0
San Antonio Center of Biomarkers of Risk for Prostate Cancer (SABOR) 0 0
EDRN Resource Network Exchange 0 0
Methylation & Proteomics-Based Detection of Bladder Cancer 0 0
PCA3 Validation Study and Urinary Reference Set 2 0
Prostate Rapid Pre-Validation Set 6 0
Prostate Reference Set Application: proPSA-Dan Chan-JHU (2008) 2 0
SELDI Phase I: Assay Validation-Prostate 0 1
SELDI Validation Study Phase II 0 3
Standard Specimen Reference Set: Prostate 0 0

Publications

Publication Name PubMed ID Journal
CYP1B1 variants are associated with prostate cancer in non-Hispanic and Hispanic Caucasians. 18544568 Carcinogenesis
Association of chromosome 8q variants with prostate cancer risk in Caucasian and Hispanic men. 19528667 Carcinogenesis
Prostate cancer detection strategies. 16630521 Curr Urol Rep
Validation of genome-wide prostate cancer associations in men of African descent. 21071540 Cancer Epidemiol. Biomarkers Prev.
Rethinking screening for breast cancer and prostate cancer. 19843904 JAMA
Single and multigenic analysis of the association between variants in 12 steroid hormone metabolism genes and risk of prostate cancer. 19505920 Cancer Epidemiol. Biomarkers Prev.
Prostate cancer risk with positive family history, normal prostate examination findings, and PSA less than 4.0 ng/mL. 17991549 Urology
Association of polymorphisms in TGFB1 and prostate cancer prognosis. 18082198 J. Urol.
Biomarkers for prostate cancer detection. 17936845 J. Urol.
Regulation of Cox-2 by cyclic AMP response element binding protein in prostate cancer: potential role for nexrutine. 18030357 Neoplasia
Prospective evaluation of operating characteristics of prostate cancer detection biomarkers. 21074193 J. Urol.
Association between an estrogen receptor alpha gene polymorphism and the risk of prostate cancer in black men. 16406987 J. Urol.
Body mass index adjusted prostate-specific antigen and its application for prostate cancer screening. 20739049 Urology
Lack of disparity in lower urinary tract symptom severity between community-dwelling non-Hispanic white, Mexican-American, and African-American men. 17445654 Urology
Urine metabolomics analysis for kidney cancer detection and biomarker discovery. 19008263 Mol. Cell Proteomics
External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population. 17169636 Urology
Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. 15998892 JAMA
Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarker. 15329895 Cancer
Limited PSA testing in indigent men in South Texas: an appropriate care or missing a prevention opportunity? 22822113 Cancer Epidemiol. Biomarkers Prev.
Temporal changes in the clinical approach to diagnosing prostate cancer. 23271768 J. Natl. Cancer Inst. Monographs
Serum adiponectin, C-peptide and leptin and risk of symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial. 19475640 Prostate
Analysis of serum total and free PSA using immunoaffinity depletion coupled to SRM: correlation with clinical immunoassay tests. 22846433 J Proteomics
Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. 16622122 J. Natl. Cancer Inst.
Global patterns of prostate cancer incidence, aggressiveness, and mortality in men of african descent. 23476788 Prostate Cancer
Future directions in the prevention of prostate cancer. 24281061 Nat Rev Clin Oncol
Focusing PSA testing on detection of high-risk prostate cancers by incorporating patient preferences into decision making. 25090603 JAMA
The impact of prostate volume, number of biopsy cores and American Urological Association symptom score on the sensitivity of cancer detection using the Prostate Cancer Prevention Trial risk calculator. 23313212 J. Urol.
Prostate Cancer Prevention Trial risk calculator 2.0 for the prediction of low- vs high-grade prostate cancer. 24862395 Urology
Predicting prostate cancer risk through incorporation of prostate cancer gene 3. 18707724 J. Urol.
Is there a role for body mass index in the assessment of prostate cancer risk on biopsy? 24747090 J. Urol.
The diagnostic value of adiponectin multimers in healthy men undergoing screening for prostate cancer. 24296854 Cancer Epidemiol. Biomarkers Prev.
Relationship of body mass index and prostate specific antigen in a population-based study. 15082010 Urol. Oncol.
Precision Medicine in Active Surveillance for Prostate Cancer: Development of the Canary-Early Detection Research Network Active Surveillance Biopsy Risk Calculator. 25819722 Eur. Urol.
Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. 15163773 N. Engl. J. Med.
Integrating the predictiveness of a marker with its performance as a classifier. 17982157 Am. J. Epidemiol.
The early detection research network surface-enhanced laser desorption and ionization prostate cancer detection study: A study in biomarker validation in genitourinary oncology. 15283893 Urol. Oncol.
What do the screening trials really tell us and where do we go from here? 24725484 Urol. Clin. North Am.
Addressing overdiagnosis and overtreatment in cancer: a prescription for change. 24807866 Lancet Oncol.
Nanomechanical biomarkers of single circulating tumor cells for detection of castration resistant prostate cancer. 25065737 Prostate
Active surveillance for prostate cancer. 21119090 JAMA
Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. 20142396 Am. J. Epidemiol.
Prostate-specific antigen in the early detection of prostate cancer. 17576986 CMAJ
Prostate cancer detection: a view of the future. 21130561 Eur. Urol.
Association of RNASEL variants with prostate cancer risk in Hispanic Caucasians and African Americans. 17908993 Clin. Cancer Res.
Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial. 17634486 J. Clin. Oncol.
Total prostate specific antigen stability confirmed after long-term storage of serum at -80C. 18550121 J. Urol.
Detection of recurrent copy number loss at Yp11.2 involving TSPY gene cluster in prostate cancer using array-based comparative genomic hybridization. 16618725 Cancer Res.
Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection. 17437804 J. Urol.
A simple-to-use method incorporating genomic markers into prostate cancer risk prediction tools facilitated future validation. 25684153 J Clin Epidemiol
VDR and SRD5A2 polymorphisms combine to increase risk for prostate cancer in both non-Hispanic White and Hispanic White men. 18483391 Clin. Cancer Res.
Biomarker-based methods for determining noncompliance in a prevention trial. 12505245 Control Clin Trials
An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. 21350221 J. Natl. Cancer Inst.
Erectile dysfunction and subsequent cardiovascular disease. 16414947 JAMA
Characterization of PacMetUT1, a recently isolated human prostate cancer cell line. 18361412 Prostate
Single and multivariate associations of MSR1, ELAC2, and RNASEL with prostate cancer in an ethnic diverse cohort of men. 20086112 Cancer Epidemiol. Biomarkers Prev.
Validation in a multiple urology practice cohort of the Prostate Cancer Prevention Trial calculator for predicting prostate cancer detection. 19836788 J. Urol.
Processing of voided urine for prostate cancer RNA biomarker analysis. 26306723 Prostate
Active Surveillance is an Appropriate Management Strategy for a Proportion of Men Diagnosed with Prostate Cancer by Prostate Specific Antigen Testing. 25636657 J. Urol.
Prostate-specific antigen levels, prostate-specific antigen kinetics, and prostate cancer prognosis: a tocsin calling for prospective studies. 17405989 J. Natl. Cancer Inst.
The Next Generation of Clinical Decision Making Tools: Development of a Real-Time Prediction Tool for Outcome of Prostate Biopsy in Response to a Continuously Evolving Prostate Cancer Landscape. 25636656 J. Urol.
Intermediate-Term Risk of Prostate Cancer is Directly Related to Baseline Prostate Specific Antigen: Implications for Reducing the Burden of Prostate Specific Antigen Screening. 25686543 J. Urol.
Improving patient prostate cancer risk assessment: Moving from static, globally-applied to dynamic, practice-specific risk calculators. 25989018 J Biomed Inform
A case control study of sarcosine as an early prostate cancer detection biomarker. 26429735 BMC Urol
Histologic Grading of Prostatic Adenocarcinoma Can Be Further Optimized: Analysis of the Relative Prognostic Strength of Individual Architectural Patterns in 1275 Patients From the Canary Retrospective Cohort. 27635949 Am. J. Surg. Pathol.
Timing of Adverse Prostate Cancer Reclassification on First Surveillance Biopsy: Results from the Canary Prostate Cancer Active Surveillance Study. 27810448 J. Urol.
Serial Percent Free Prostate Specific Antigen in Combination with Prostate Specific Antigen for Population Based Early Detection of Prostate Cancer. 26979652 J. Urol.
DNA methylation screening of primary prostate tumors identifies SRD5A2 and CYP11A1 as candidate markers for assessing risk of biochemical recurrence. 26332453 Prostate
A diagnosis of prostate cancer and pursuit of active surveillance is not followed by weight loss: potential for a teachable moment. 27431498 Prostate Cancer Prostatic Dis.
Semaphorin 3B and 3F single nucleotide polymorphisms are associated with prostate cancer risk and poor prognosis. 19683737 J. Urol.
The association of body mass index and prostate-specific antigen in a population-based study. 15668913 Cancer
Yearly prostate specific antigen and digital rectal examination fluctuations in a screened population. 19286205 J. Urol.
Androgen receptor length polymorphism associated with prostate cancer risk in Hispanic men. 12394768 J. Urol.
Helicobacter Pylori Infection in Texas Hispanic and Non-Hispanic White Men: Implications for Gastric Cancer Risk Disparities. 28413904 Am J Mens Health

To update protocols, publications, biomarkers, or science data, please contact the Informatics Center.

Addresses

UTHSCSA
University of Texas Health Science Center at San Antonio

To update addresses, please visit the Data Management and Coordinating Center.

Announcement 10/23/2017

Three new FOAs on the Human Tumor Atlas and associated with the Cancer Moonshot Initiative have been released. Please click here for more information.

32nd SC Meeting
Thank you to everyone who made the 32nd EDRN Steering Committee meeting a success. The next event is the 10th EDRN Scientific Workshop from March 6-8, 2018 in Bethesda, MD. More information about this Workshop will be sent soon. Click here to view the flyer.
EDRN Founder Honored

Dr. Sudhir Srivastava was honored with the Distinguished Service Award from the American Pancreatic Association at the group's annual meeting this year, for his outstanding commitment to pancreatology.